These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30177482)

  • 1. Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature.
    Ji G; Zhang C; Guan S; Yao X
    Clin Breast Cancer; 2018 Oct; 18(5):e759-e765. PubMed ID: 30177482
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
    Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.
    Figura NB; Long W; Yu M; Robinson TJ; Mokhtari S; Etame AB; Tran ND; Diaz R; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
    Breast Cancer Res Treat; 2018 Jun; 169(2):391-396. PubMed ID: 29392582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    Ricciardi GRR; Russo A; Franchina T; Schifano S; Mastroeni G; Santacaterina A; Adamo V
    BMC Cancer; 2018 Jan; 18(1):97. PubMed ID: 29370839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.
    Mir O; Ropert S; Alexandre J; Lemare F; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1978-80. PubMed ID: 18845838
    [No Abstract]   [Full Text] [Related]  

  • 6. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
    How J; Mann J; Laczniak AN; Baggstrom MQ
    Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
    Patil A; Sherbet GV
    Cancer Lett; 2015 Mar; 358(2):93-99. PubMed ID: 25529010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current challenges in the management of breast cancer brain metastases.
    O'Sullivan CC; Davarpanah NN; Abraham J; Bates SE
    Semin Oncol; 2017 Apr; 44(2):85-100. PubMed ID: 28923217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
    Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
    Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 in brain metastases: issues of concordance, survival, and treatment.
    Fuchs IB; Loebbecke M; Buhler H; Stoltenburg-Didinger G; Heine B; Lichtenegger W; Schaller G
    J Clin Oncol; 2002 Oct; 20(19):4130-3. PubMed ID: 12351617
    [No Abstract]   [Full Text] [Related]  

  • 16. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
    Sakata Y; Kawamura K; Shingu N; Ichikado K
    Lung Cancer; 2016 Sep; 99():120-2. PubMed ID: 27565925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Brain metastases in breast cancer: a special disease course for HER2 positive tumors].
    Hurkens KP; Hupperets PS; Creemers GJ; Erdkamp FL; van de Vijver KK; Tjan-Heijnen VC
    Ned Tijdschr Geneeskd; 2008 Dec; 152(50):2701-6. PubMed ID: 19192581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
    Stemmler HJ; Schmitt M; Harbeck N; Willems A; Bernhard H; Lässig D; Schoenberg S; Heinemann V
    Oncol Rep; 2006 May; 15(5):1373-7. PubMed ID: 16596213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab.
    Baculi RH; Suki S; Nisbett J; Leeds N; Groves M
    J Clin Oncol; 2001 Jul; 19(13):3297-8. PubMed ID: 11432901
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.